

1 **Programmed mutation of liver fluke granulin using CRISPR/Cas9 attenuates**  
2 **virulence of infection-induced hepatobiliary morbidity**

3  
4 **Patpicha Arunsan<sup>1,2,¶</sup>, Wannaporn Ittiprasert<sup>2,¶</sup>, Michael J. Smout<sup>3,¶</sup>, Christina J.**  
5 **Cochran<sup>2</sup>, Victoria H. Mann<sup>2</sup>, Sujittra Chaiyadet<sup>1</sup>, Shannon E. Karinshak<sup>2</sup>, Banchob**  
6 **Sripa<sup>4</sup>, Neil D. Young<sup>5</sup>, Javier Sotillo<sup>3</sup>, Alex Loukas<sup>3,\*</sup>, Paul J. Brindley<sup>2,\*</sup> and Thewarach**  
7 **Laha<sup>1,\*</sup>**

8  
9 <sup>1</sup>Department of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002,  
10 Thailand

11 <sup>2</sup>Department of Microbiology, Immunology and Tropical Medicine, and Research Center for  
12 Neglected Diseases of Poverty, School of Medicine & Health Sciences, George Washington  
13 University, Washington, DC 20037, USA

14 <sup>3</sup>Centre for Biodiscovery and Molecular Development of Therapeutics, Australian Institute of  
15 Tropical Health and Medicine, James Cook University, Cairns, QLD 4878, Australia

16 <sup>4</sup>Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002,  
17 Thailand

18 <sup>5</sup>Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Parkville,  
19 Victoria 3010 Australia

20  
21 <sup>¶</sup>These authors contributed equally. <sup>\*</sup>These authors contributed equally.

22  
23 <sup>\*</sup>Correspondence: Thewarach Laha, Department of Parasitology, Faculty of Medicine, Khon  
24 Kaen University, 123 Mittraparp Highway, Khon Kaen 40002 Thailand. Phone +66 43 348387.  
25 E-mail: [thewa\\_la@kku.ac.th](mailto:thewa_la@kku.ac.th)

26  
27 <sup>\*</sup>Correspondence: Alex Loukas, Centre for Biodiscovery and Molecular Development of  
28 Therapeutics, Queensland Tropical Health Alliance, Australian Institute of Tropical Health and  
29 Medicine, James Cook University, Cairns Campus, Cairns, Queensland 4878, Australia; E-mail,  
30 [alex.loukas@jcu.edu.au](mailto:alex.loukas@jcu.edu.au)

31  
32 <sup>\*</sup>Correspondence: Paul J. Brindley, Department of Microbiology, Immunology and Tropical  
33 Medicine, and Research Center for Neglected Diseases of Poverty, School of Medicine & Health  
34 Sciences, George Washington University, Washington, DC 20037, USA. E-mail:  
35 [pbrindley@email.gwu.edu](mailto:pbrindley@email.gwu.edu)

36  
37  
38 **KEY WORDS:** *Opisthorchis viverrini*; liver fluke; genome editing; CRISPR/Cas9;  
39 opisthorchiasis; *granulin*; growth factor; cholangiocarcinoma;

46 **Abstract**

47  
48 Infections with several flatworm parasites represent group 1 biological carcinogens, *i.e.* definite  
49 causes of cancer. Infection with the food-borne liver fluke *Opisthorchis viverrini* causes  
50 cholangiocarcinoma (CCA). Whereas the causative agent for most cancers, including CCA in the  
51 West, remains obscure, the principal risk factor for CCA in Thailand is opisthorchiasis. We  
52 exploited this established link to explore the role of the secreted parasite growth factor termed  
53 liver fluke granulin (*Ov-GRN-1*) in pre-malignant lesions of the biliary tract. We targeted  
54 the *Ov-grn-1* gene for programmed knockout and investigated gene-edited parasites *in vitro* and  
55 in experimentally infected hamsters. Both adult and juvenile stages of the liver fluke were  
56 transfected with a plasmid encoding a guide RNA sequence specific for exon 1 of *Ov-grn-1* and  
57 the Cas9 nuclease. Deep sequencing of amplicon libraries from genomic DNA from gene-edited  
58 parasites exhibited programmed, Cas9-catalyzed mutations within the *Ov-grn-1* locus, and  
59 tandem analyses by RT-PCR and western blot revealed rapid depletion of *Ov-grn-1* transcripts  
60 and protein. Newly excysted juvenile flukes that had undergone editing of *Ov-grn-1* colonized  
61 the biliary tract, grew and developed over a period of 60 days, were active and motile, and  
62 induced a clinically relevant pathophysiological tissue phenotype of attenuated biliary  
63 hyperplasia and fibrosis in comparison to infection with wild type flukes. This is the first report  
64 of gene knock-out using CRISPR/Cas9 in a parasitic flatworm, demonstrating the activity and  
65 utility of the process for functional genomics in these pathogens. The striking clinical phenotype  
66 highlights the role in virulence that liver fluke growth factors play in biliary tract morbidity  
67 during chronic opisthorchiasis.

68  
69 Liver fluke infection caused by species of *Opisthorchis* and *Clonorchis* remains a major public  
70 health problem in East Asia and Eastern Europe. *O. viverrini* is endemic in Thailand and Laos,  
71 where ~10 million people are infected with the parasite<sup>1</sup>. There is no stronger link between a  
72 human malignancy and a parasitic infection than that between CCA and infection with *O.*  
73 *viverrini*<sup>2</sup>. In endemic regions such as Northeastern Thailand, infection causes hepatobiliary  
74 diseases including cholangitis and periductal fibrosis - a major risk factor for CCA<sup>3</sup>. The north  
75 of Thailand suffers the highest incidence of CCA in the world, often exceeding 80 cases per  
76 100,000 population, and for which up to 20,000 people annually are admitted for surgery.  
77 Unfortunately, prognosis for fluke-induced cancer is poor<sup>1,4,5</sup>.

78  
79 How and why opisthorchiasis induces cholangiocarcinogenesis is likely multi-factorial, including  
80 mechanical irritation of the biliary tract during migration and feeding of the liver fluke,  
81 inflammatory molecules released by the parasite, and nitrosamines in fermented foods that are a  
82 dietary staple in northern Thailand. To survive in the hostile host environment, parasitic  
83 helminths produce an assortment of excretory/secretory (ES) products including proteins with  
84 diverse roles at the host-parasite interface. This interaction has long been thought but not fully  
85 understood to modify cellular homeostasis and contribute to malignant transformation during  
86 chronic opisthorchiasis<sup>6</sup>. Feeding activity of the liver fluke inflicts wounds in the biliary tree,  
87 lesions that undergo protracted cycles of repair and re-injury during chronic infection. The liver  
88 fluke secretes mediators that accelerate wound resolution in cholangiocytes, an outcome that can  
89 be compromised following silencing of expression of *Ov-grn-1* using RNA interference<sup>7,8</sup>. We  
90 hypothesize that proliferation of biliary epithelial cells induced by *Ov-GRN-1* is a pivotal factor  
91 in establishing a tumorigenic microenvironment in livers of infected individuals.

92  
93 Progress with development of genetic tools for functional genomic studies with platyhelminth  
94 parasites has been limited to date<sup>9</sup>. The use of clustered regularly interspaced short palindromic  
95 repeats (CRISPR) associated with Cas9, an RNA-guided DNA endonuclease enzyme, has  
96 revolutionized genome editing in biomedicine, agriculture and biology at large<sup>10,11</sup>. Progress  
97 with CRISPR/Cas9 in numerous eukaryotes including the nematodes *Caenorhabditis elegans*  
98 and *Strongyloides stercoralis* has been described<sup>11-14</sup>, but this form of gene editing has not been  
99 reported for flatworm parasites. Here, we deployed CRISPR/Cas9 to knockout (mutate) the *Ov-*  
100 *grn-1* gene and assess the virulence of gene-edited flukes *in vitro* and *in vivo* in a hamster model  
101 of opisthorchiasis.

102  
103 A construct termed pCas 9-*Ov-grn-1* (Fig. 1a and Supplementary Fig. 1a) was assembled  
104 following assessment of the *Ov-grn-1* locus in the annotated genome sequence of *O. viverrini*<sup>15</sup>.  
105 Nucleotide sequences in pCas 9-*Ov-grn-1* were confirmed by Sanger cycle sequencing; pCas 9-  
106 *Ov-grn-1* encodes the Cas9 nuclease and a single guide RNA (sgRNA) complementary to a  
107 target sequence 5'-GATTCATCTACAAGTGTTGA within exon 1 of *Ov-grn-1*. The predicted  
108 programmed cleavage site was predicted to be at three residues upstream of a CGG proto-spacer  
109 adjacent motif sequence (PAM) in exon 1 of *Ov-grn-1* (Fig. 1b; Supplementary Fig. 1b). Adult  
110 *O. viverrini* flukes recovered from experimentally infected hamsters were subjected *in vitro* to  
111 square wave electroporation<sup>8</sup> in the presence of pCas 9-*Ov-grn-1* DNA, and thereafter  
112 maintained in culture for three weeks. The activity of CRISPR/Cas9 was evaluated by two  
113 approaches.

114  
115 First, quantitative PCR (qPCR) was employed, which relies on the inefficiency of binding of a  
116 primer (here termed OVR-F) overlapping the target genomic sequence of the gRNA, i.e. where  
117 mutations are expected to have occurred, compared to the binding efficiency of flanking primers,  
118 i.e. outside the mutated region<sup>16,17</sup> (flanking primers termed OUT and OUT-R) (Fig. 1b).  
119 Genomic DNA (gDNA) templates were investigated by quantitative PCR to quantify the  
120 efficiency of programmed gene-editing at the target locus; the ratio between the OVR-OUT-R  
121 products and OUT-F-OUT-R products provided an estimate of the amplification fold-reduction  
122 in the sample of CRISPR/Cas9-edited compared to gDNA from control, wild type liver flukes at  
123 the target sequence of the sgRNA, i.e. the annealing site for the OVR primer. A reduction in  
124 relative fold amplification of 2.7% was detected in gDNA from the Cas9-treated worms (Fig. 1e;  
125 Supplementary Fig. 1c).

126  
127 Second, to identify and quantify the mutations that arose in the genome of *Ov-grn-1*-edited  
128 (termed  $\Delta$ *Ov-grn-1*) flukes, we used an amplicon-sequencing approach. A targeted (amplicon)  
129 sequence library was constructed from genomic DNA from some of the flukes. A 173 bp  
130 fragment spanning the predicted double stranded break site of *Ov-grn-1* was amplified from the  
131 gDNAs primed with oligonucleotides flanking 1496-1668 nt of *Ov-grn-1*. Adaptors and barcodes  
132 were ligated into these amplicon libraries. The MiSeq libraries were undertaken by Illumina  
133 MiSeq-based deep sequencing. Insertion-deletion (INDEL)/mutation profiles in the sequence  
134 reads were compared in multiple sequence alignment with wild type reference template sequence  
135 (1496-1668 nt) of *Ov-grn-1*. Each amplicon was sequenced on the MiSeq Illumina platform and  
136 quantified the gene editing frequency by the CRISPResso pipeline<sup>18,19</sup>. More than 2 million  
137 sequenced reads were aligned against the reference sequence, which predicted the presence of

138 27, 616 non-homologous end joining (NHEJ) reads, specifically 170 reads with insertions  
139 (0.6%), 193 reads with deletions (0.7%) and 27,277 reads with substitutions (98.7%). At large,  
140 1.25% of the sequenced reads exhibited NHEJ mutations (Fig. 1c). Among these NHEJ reads,  
141 there were >100 forms exhibiting mutations that would disrupt the coding sequencing of *Ov-grn-*  
142 *I*. Four representatives of the INDEL-bearing traces aligned with the WT allele are presented in  
143 Supplementary Fig. 1b. The Illumina sequencing reads are available as GenBank accessions  
144 SRR5764463-5764618, at <https://www.ncbi.nlm.nih.gov/Traces/study/?acc=SRP110673>,  
145 Bioproject, [www.ncbi.nlm.nih.gov/bioproject/PRJNA385864](http://www.ncbi.nlm.nih.gov/bioproject/PRJNA385864).

146  
147 Effects of gene editing on transcription and protein expression were investigated. Levels of both  
148 *Ov-grn-I* mRNA transcripts as determined by RT-PCR and of granulin, as detected by western  
149 blot with anti-*Ov-GRN-1* sera, fell significantly from days 1 and 2 after transfection, respectively  
150 ( $P \leq 0.0001$ ; Fig. 1d, e; Supplementary Fig. 1c). Expression levels of two reference genes, the  
151 actin transcript (Supplementary Fig. 1c) and the *Ov-TSP-2* tegument protein (Fig. 1d), were not  
152 influenced by the programmed mutation of *Ov-grn-I*.

153 To investigate whether gene editing of *Ov-grn-I* impacted *in vitro* indicators of pathogenesis, the  
154 capacity of ES products from WT, mock-transfected and gene-edited flukes to drive proliferation  
155 and scratch wound repair of the H69 human primary cholangiocyte cell line was assessed. ES  
156 from WT and mock-transfected adult flukes stimulated cell proliferation and wound closure  
157 whereas an equivalent amount of ES products from  $\Delta$ *Ov-grn-I* flukes resulted in significantly  
158 reduced cell proliferation over the six day course of the assay ( $P \leq 0.0001$ ; Fig. 2a, b;  
159 Supplementary Fig. 2a, b) and significantly reduced *in vitro* wound closure over 36 hours ( $P \leq$   
160  $0.0001$ ; Fig. 2c; Supplementary Fig. 2c, d), consistent with a reduction in the amount of *Ov-*  
161 *GRN-1* secreted from the gene-edited liver flukes.

162 Notwithstanding the noteworthy effects observed with gene-edited, adult developmental forms,  
163 the metacercaria (MC) (Fig. 3a) is the infective stage of *O. viverrini* for humans. Accordingly,  
164 we investigated gene knockout in MC. No effect was apparent on *Ov-grn-I* transcript levels in  
165 MC, (Supplementary Fig. 3), suggesting that delivery of the pCas 9-*Ov-grn-I* by electroporation  
166 through the MC cyst wall was ineffective. Exposure to bile acids and gastric enzymes results in  
167 excystation of *O. viverrini* MC in the duodenum of the infected mammalian host. We mimicked  
168 this process *in vitro* using trypsin to release the newly excysted juvenile worms (NEJ; Fig. 3b),  
169 after which NEJ were subjected to electroporation with CRISPR/Cas9 constructs as described for  
170 adult flukes. Marked depletion of *Ov-grn-I* transcripts ( $P < 0.0001$ ) followed this manipulation  
171 (Fig. 3c).

172  
173 In parallel, hamsters were infected, using gastric gavage, with 100  $\Delta$ *Ov-grn-I* NEJ or WT NEJ  
174 immediately after electroporation. At necropsy of the hamsters two to three weeks later, it was  
175 clear that  $\Delta$ *Ov-grn-I* flukes had colonized the bile ducts in similar numbers to WT flukes, and  
176 were similarly motile. Strikingly, the infection with  $\Delta$ *Ov-grn-I* parasites failed to induce the  
177 marked hyperplasia of the bile duct epithelia characteristic of infection with WT flukes.  
178 Specifically, infection with WT flukes had induced markedly disordered, hyperplastic growth of  
179 the epithelium adjacent to the parasites; at day 14, five times more than in uninfected controls ( $P$   
180  $\leq 0.0001$ ) (Fig. 3d) whereas infection with the  $\Delta$ *Ov-grn-I* flukes (Fig. 3e) provoked 11-fold less  
181 ( $P \leq 0.0001$ ) biliary hyperplasia than WT fluke infected livers (day 14, 145% thickening  
182 compared to uninfected controls;  $P \leq 0.01$ ) (Fig. 3g). Indeed, the bile ducts from hamsters

183 infected with the  $\Delta Ov-grn-1$  flukes generally resembled those of the control, uninfected hamsters  
184 (Fig. 3f).

185 To assess long-term survival of  $\Delta Ov-grn-1$  NEJ in hamsters and associated chronic biliary  
186 morbidity, hamsters were infected with  $\Delta Ov-grn-1$  and WT NEJ, and adult flukes were  
187 recovered and counted from the livers 60 days post-infection. Similar numbers of worms were  
188 recovered from both control and gene-edited liver fluke-infected hamsters (Fig. 4a). To assess  
189 the impact of infection with  $\Delta Ov-grn-1$  on markers of chronic opisthorchiasis such as biliary  
190 fibrosis, liver sections from infected hamsters were stained with Picro-Sirius Red to detect  
191 collagen bundles in the biliary tract (Fig. 4b). Minimal deposits of collagen were seen in the  
192 periductal regions of the biliary tract of the control, uninfected hamsters whereas hamsters  
193 infected with WT flukes had thick bands of collagen surrounding enlarged bile ducts in the  
194 vicinity of the flukes. Significantly less collagen (28%) was detected in periductal sites of the  
195 biliary tract infected with  $\Delta Ov-grn-1$  flukes ( $P < 0.001$ ) compared to livers of hamsters infected  
196 with WT flukes (Fig. 4b, c). To further assess fibrosis in hepatobiliary tract, we stained for  
197 smooth muscle actin (ACTA2), an established marker of hepatic fibrosis<sup>20</sup>, by probing thin  
198 tissue sections with anti-ACTA2 antibody. Livers of hamsters infected with WT flukes showed  
199 densely packed collagen fibrils that stained for ACTA-2 in periductal regions proximal to the  
200 parasites. In contrast, livers from hamsters infected with  $\Delta Ov-grn-1$  flukes displayed an irregular  
201 distribution of less dense collagen fibrils with less ACTA2-specific fluorescence (Fig. 4d;  
202 Supplementary Fig. 4). The intensity of ACTA2-specific fluorescence was quantified by  
203 measuring fluorescence intensity; livers from  $\Delta Ov-grn-1$  fluke-infected hamsters showed 94%  
204 reduction ( $P < 0.01$ ) of median fluorescence values relative to controls infected with WT flukes  
205 (Fig. 4e).

206 Despite reaching high levels of significance, the data range was high for both markers of  
207 collagen deposition assessed. We hypothesized that this was likely due to inconsistencies in the  
208 electroporation-mediated delivery of the CRISPR/Cas9 constructs between individual flukes. We  
209 therefore collected  $\Delta Ov-grn-1$  and WT flukes from hamster bile ducts 60 days post-infection and  
210 assessed *Ov-grn-1* gene expression from individual flukes (Fig. 4f). We then separated flukes  
211 into three groups based on *Ov-grn-1* mRNA expression levels: >100% relative to WT average;  
212 10-100% relative to WT average; <10% relative to WT average. We pooled genomic DNA from  
213 flukes to form the three groups described above and assessed mutation frequencies. In line with  
214 the *Ov-grn-1* mRNA expression profiles,  $\Delta Ov-grn-1$  flukes where gene editing appeared to be  
215 relatively inefficient (i.e. >100% mRNA expression relative to WT average) had an average  
216 mutation frequency of just 0.7%, whereas  $\Delta Ov-grn-1$  flukes where gene editing appeared to be  
217 moderately efficient (10-100% mRNA expression relative to WT average) had an average  
218 mutation frequency of 3.2%;  $\Delta Ov-grn-1$  flukes where gene editing appeared to be highly  
219 efficient (<10% mRNA expression) had an average mutation frequency of 4.6% (Fig. 4f). The  
220 combined mutation frequency was 2.7% (Fig. 4f), notably similar to the 2.7% mutation rate  
221 detected when  $\Delta Ov-grn-1$  flukes were cultured *in vitro* for 21 days (Fig 1e and Supplementary  
222 Fig. 1c).

223 In overview, we describe the first example of successful somatic gene editing of a parasitic  
224 flatworm using CRISPR/Cas9. The results revealed that gene editing induced disruption of  
225 expression of *Ov-grn-1* in liver flukes, which in turn revealed a pathologically relevant  
226 phenotype in the mammalian biliary tract. Following programmed gene editing, the lesion was

227 apparently repaired by non-homologous end joining. The bacterial Type II Cas9 system is active  
228 in this liver fluke, and we conjecture that Cas9-catalyzed gene editing will be active in  
229 trematodes and parasitic platyhelminths at large. As noted, whereas the causative agent for many  
230 cancers, including CCA in the West, remains obscure, the principal risk factor for CCA in  
231 Thailand and Laos has long been established - infection with *O. viverrini*. Cas9-based gene  
232 editing and the hamster model of human opisthorchiasis utilized herein, including genetic  
233 manipulation of the infective NEJ parasite, together provide a facile, functional genomics system  
234 to interrogate parasite pathogenicity and carcinogenicity in an informative rodent model of liver  
235 fluke infection-induced malignancy.

## 236 237 **Materials and Methods**

### 238 239 ***Opisthorchis viverrini* parasite preparation**

240  
241 Metacercariae (MC) of *O. viverrini* were isolated from the naturally infected cyprinid fish by  
242 pepsin digestion as previously described<sup>21</sup>. In brief, fishes were minced with an electric blender,  
243 and then minced tissues were digested with 0.25% porcine pepsin, 1.5% HCl in 150 mM NaCl at  
244 37°C for 2 hours. After tissue digestion, the tissue mixture was filtered sequentially through  
245 1,100, 350, 250, and 140 µm diameter pore size sieves; the final filtrate sedimented by gravity  
246 and the aqueous supernatant was discarded. The *O. viverrini* MC enriched-sediment was washed  
247 once with 150 mM NaCl (normal saline solution, NSS), and the identity of *O. viverrini* MC  
248 confirmed using a stereomicroscope. The *O. viverrini* MCs were stored in NSS at 4°C until used.  
249 The newly excysted-juvenile (NEJs) were prepared from MC in 0.25% trypsin in 1×PBS  
250 containing 2× 200U/ml penicillin, 200 µg/ml streptomycin (Gibco) (2× Pen/Strep) for 5 min at  
251 RT prior to separate the cyst walls from juvenile parasite by insulin needle<sup>7,22</sup>. NEJ were  
252 transferred to RPMI medium containing 1% glucose, 2 g/L NaHCO<sub>3</sub>, 2× Pen/Strep and 1 µM E-  
253 64 protease inhibitor (Thermo Fisher Scientific) and maintained at 37°C, 5% CO<sub>2</sub> for 60 min  
254 before use.

255  
256 To obtain adult developmental stages of the liver fluke, Syrian golden hamsters (*Mesocricetus*  
257 *auratus*) were infected at 6-8 weeks of age with 50 MC per hamster by intragastric tube<sup>23</sup>. The  
258 hamsters were maintained at the Animal Facility of Faculty of Medicine, Khon Kaen University,  
259 Khon Kaen, Thailand. Sixty days after infection, hamsters were euthanized and the liver flukes  
260 collected, as described<sup>22,23</sup>. The study protocol was reviewed and approved by the Animal Ethics  
261 Committee of Khon Kaen University. The study adhered to standard guidelines of the Ethics of  
262 Animal Experimentation of the National Research Council of Thailand (approval number  
263 ACUC-KKU-61/60).

### 264 265 **Vector and guide RNA targeting exon 1 of *Ov-grn-1***

266  
267 To edit the gene *Ov-grn-1* that encodes *O. viverrini* granulin-1 (6287 bp, mRNA GenBank  
268 accession FJ436341.1), CRISPR online tools including CRISPR design (<http://crispr.mit.edu/>)  
269 and ChopChop (<http://chopchop.cbu.uib.no/>) were employed to design a guide RNA (gRNA)  
270 targeting exon 1 *Ov-grn-1* gene at nucleotide position 1589-1608,  
271 GATTCATCTACAAGTGTTGA (Fig. 1a and 1b). A CRISPR/Cas9 encoding vector encoding  
272 the above gRNA under the control of the mammalian U6 promoter and encoding Cas9 (with

273 nuclear localization signal 1 and 2) driven by the CMV promoter was assembled (GeneArt  
274 CRISPR Nuclease Vector Kit, Thermo Fisher), and termed pCas-*Ov-grn-1* (Supplementary Fig.  
275 1a). *Escherichia coli* TOP-10 competent cells were transformed with pCas-*Ov-grn-1* and vector  
276 plasmid recovered from cultures of a positive clone (NucleoBond Xtra Midi, Macherey-Nagel  
277 GmbH, Germany). The nucleotide sequence of pCas-*Ov-grn-1* was confirmed by Sanger direct  
278 sequencing.

### 279 280 **Transfection of liver flukes with pCas-*Ov-grn-1***

281  
282 Twenty mature flukes were transfected with 10 µg pCas-*Ov-grn-1* pDNA in ~500 µl RPMI-1640  
283 (Sigma) by electroporation. The electroporation was performed in 4 mm cuvettes (Bio-Rad) with  
284 a single square wave pulse of 125 volts for 20 ms using a Gene Pulser Xcell (Bio-Rad). Flukes  
285 were then washed several times with NSS and an additional 5 times with RPMI-1640 containing  
286 2× Pen/Strep. Flukes were cultured in RPMI-1640 containing 2× Pen/Step at 37°C in 5% CO<sub>2</sub>  
287 atmosphere<sup>7,24</sup>. Two control groups were included: wild type (WT) mature flukes and ‘mock’  
288 control flukes which were exposed to identical electroporation conditions with RPMI-1640 and  
289 1× Pen/Strep in the absence of plasmid DNA. The adult flukes were observed and collected after  
290 1, 2, 3, 5, 7, 14 and 21 days of culture following pCas-*Ov-grn-1* transfection. RNA and protein  
291 was extracted from flukes and *Ov-grn-1* mRNA expression was assessed by RT-qPCR and *Ov-*  
292 *GRN-1* protein expression was assessed by western blot. Mutations and/or insertions-deletions  
293 (INDELs) resulting from CRISPR/Cas were analyzed by CRISPR efficiency estimation<sup>17,25</sup> and  
294 MiSeq Next Generation Sequencing (NGS).

295  
296 MC and NEJ (750 parasites per cuvette) were subjected to square wave electroporation in the  
297 presence of pCas-*Ov-grn-1* pDNA as described above for adult flukes. The parasites were  
298 washed as above and cultured in RPMI complete medium (10% FBS, 2× Pen/Strep) at 37°C in  
299 5% CO<sub>2</sub> in air. The parasites were collected on days 1, 2, 3 and 5 after transfection and *Ov-grn-1*  
300 transcript levels were ascertained by RT-qPCR, as above.

### 301 302 **Extraction of nucleic acids**

303  
304 RNA was extracted from pooled or individual flukes using TRIZOL (Invitrogen) according to  
305 the manufacturer’s recommendations. Concentration of RNA was estimated by 260 nm by  
306 NanoVue spectrophotometer. Genomic DNA from individual or pooled (25 worms) flukes was  
307 extracted using the QIAamp DNA Mini Kit (Qiagen, Valencia, CA). The dual RNA and DNA  
308 extraction technique was used for some experiments with individual worms using RNAzol<sup>®</sup>RT  
309 (Molecular Research Center, Inc.) and DNAzol (Molecular Research Center, Inc.)<sup>26,27</sup>. In brief,  
310 each worm was homogenized in RNAzol<sup>®</sup>RT using a motorized pestle, the DNA and protein  
311 from the lysate was precipitated using DNase-RNase-free water. The aqueous top solution was  
312 transferred into isopropanol to precipitate the RNA. The DNA/protein pellet was resuspended in  
313 DNAzol<sup>®</sup> RT, and DNA extracted as per the manufacturer’s instructions. Individual RNA  
314 samples were evaluated for *Ov-grn-1* expression. To assess variations in *Ov-grn-1* transcript  
315 levels, individual flukes were assigned into 3 groups; <10% of *Ov-grn-1* transcript fold change  
316 (fc) compared to WT, 10-70% *Ov-grn-1* transcript fc compared to WT, and 100-120% *Ov-grn-1*  
317 transcript fc compared to WT. Genomic DNA from individual worms was used to assess  
318 CRISPR efficiency and estimate mutation levels<sup>25,28</sup>. Estimates of mutation efficiency positively

319 correlated with transcripts levels of *Ov-grn-1* transcript level (**Fig. 4f**). Pooled genomic DNA  
320 samples from low to high *Ov-grn-1* transcript levels and high to low percent mutations from  
321 experimental groups were prepared for next-generation Illumina sequencing.  
322

### 323 **Quantitative Real-time PCR**

324  
325 Complementary DNA (cDNA) was synthesized from parasite total RNA using an iScript cDNA  
326 synthesis kit (Thermo Fisher Scientific) prior to proceeding with quantitative real-time PCR (RT-  
327 qPCR). RT-qPCR was performed with biological triplicate samples using a SYBR Green kit  
328 (TAKARA Perfect Real-time Kit) according to the manufacturer's recommendation in a Light  
329 Cycler 480 II thermal cycler (Roche). Each RT-qPCR reaction consisted of 7.5  $\mu$ l SYBR Green  
330 Master Mix, 0.5  $\mu$ l (10  $\mu$ M) each of specific forward and reverse primers for *Ov-grn-1* (Fig. 1b)  
331 (forward primer, *Ov-grn-1*-RT-F: 5'-GGGATCGGTTAGTCTAATCTCC and reverse primer,  
332 *Ov-grn-1*-RT-R: 5'-GATCATGGGGGTTCACTGTC), amplifying 359 base pairs (bp) of the  
333 product (position 7-365 nt of *O. viverrini* granulin-1 mRNA GenBank accession FJ436341.1), 2  
334  $\mu$ l of cDNA and distilled water to a final volume of 15  $\mu$ l. The thermal cycle was a single  
335 initiation cycle at 95°C for 3 min followed by 40 cycles of denaturation at 95°C for 30 sec,  
336 annealing at 55°C for 30 sec, extension at 72°C for 45 sec and a final extension at 72°C for 10  
337 min. The endogenous actin gene (GenBank accession AY005475) was used as a housekeeping  
338 control<sup>7,24</sup> (forward primer, *Ov-actin*-F: 5'-AGCCAACCGAGAGAAGATGA and reverse  
339 primer *Ov-actin*-R: 5'-ACCTGACCATCAGGCAGTTC). The *Ov-grn-1* transcript fold change  
340 was calculated by 2<sup>(- $\Delta\Delta$ Ct)</sup> method using *Ov-actin* for normalization<sup>7,24,29</sup>. Means and standard  
341 deviations were calculated using Graph Pad Prism software; two-way ANOVA.  
342

### 343 **Rabbit anti-*Ov*-GRN-1 antiserum and immunoblot analysis**

344  
345 One milligram of adjuvanted recombinant *Ov*-GRN-1 protein<sup>30</sup> was used to subcutaneously  
346 inject an outbred New Zealand White rabbit. The rabbit was boosted twice with 500  $\mu$ g of  
347 adjuvanted protein and two weeks after the last booster the rabbit was sacrificed for blood  
348 collection via cardiac puncture. The Animal Ethics Committee of Khon Kaen University  
349 approved the protocols used for animal experimentation, based on the guidelines of the National  
350 Research Council of Thailand for Ethics of Animal Experimentation (ACUC-KKU-61/60). *Ov*-  
351 GRN-1 protein levels were determined by western blot using rabbit anti-recombinant *Ov*-GRN-1  
352 antiserum. The adult flukes from either WT or  $\Delta$ *Ov-grn-1* groups were collected individually at  
353 days 1, 2, 3, 5, 7, 14 and 21 after electroporation (3 flukes per group). Groups of 3 flukes were  
354 homogenized by sonication (Sonics & Materials) in 1 $\times$  PBS with alternating pulses of 5 sec  
355 duration (with 5 sec pause between pulses) for 45 sec at 4°C. The homogenate was centrifuged at  
356 13,000 g at 4°C for 30 min and the supernatant collected and stored at -20°C. Protein  
357 concentration of fluke homogenates was measured using the Bradford assay and homogenates  
358 were electrophoresed on 15% SDS-PAGE gels. Proteins were transblotted onto nitrocellulose  
359 membrane using a Mini Trans-Blot Cell (Bio-Rad). Membrane strips containing 2  $\mu$ g of total  
360 protein were washed with 0.5% Tween-20 in PBS (PBST) then blocked for 1 hour with 5%  
361 skimmed milk in PBST. Strips were incubated with rabbit anti-*Ov*-GRN-1 serum or pre-  
362 immunization serum diluted 1:50 with 1% skimmed milk in PBST and incubated with shaking  
363 for 2 h. Strips were washed then incubated for 1 hour with horseradish peroxidase (HRP)-goat  
364 anti-rabbit IgG (Invitrogen) (diluted 1:1,000 in antibody buffer). The strips were washed again



365 and color reactions were detected by enhanced chemiluminescence (ECL) substrate (GE  
366 Healthcare Life Sciences) and imaged using an Image Quant LAS 4000 mini (GE Healthcare  
367 Life Sciences). As a control protein also derived from the tegument of *O. viverrini* flukes, we  
368 assessed the protein expression levels of *Ov*-TSP-2 by western blot using a specific antibody  
369 raised to the recombinant protein<sup>31</sup>. Relative protein expression levels from western blots were  
370 measured by densitometry using Image J (<https://imagej.nih.gov/ij/download.html>). Protein  
371 expression levels were compared statistically between groups using independent *t*-tests.  
372

### 373 CRISPR/Cas efficiency and mutation levels estimated by quantitative SYBR green PCR

374  
375 Adult flukes were collected on days 1, 2, 3, 5, 7, 14 and 21 after pCas-*Ov-grn-1* transfection.  
376 Each individual fluke DNA was investigated for mutation(s) around the expected double  
377 stranded break (DSB) site by using three-primers; 2 forward primers and 1 reverse primer; *Ov*-  
378 *grn-1*-OUT-F, *Ov-grn-1*-OVR-F and *Ov-grn-1*-reverse, respectively. The primer pair of *Ov*-  
379 *grn-1*-OUT-F and *Ov-grn-1*-reverse was used for amplify the fragment flanking (1496-2312 nt)  
380 the DSB, while another primer pair (*Ov-grn-1*-OVR-F and *Ov-grn-1*-reverse) was amplify  
381 overlap of DSB site (1599-2312) (**Fig. 1b**). Both primer pairs exhibited equivalent amplification  
382 efficiency with genomic DNA from WT flukes. The OUT and OVR amplicons were 450 and 347  
383 bp, respectively, using PCR conditions using 7.5 µl of SYBR Green Master Mix (TAKARA  
384 Perfect Real-time Kit), 0.5 µl (0.4 µM) of each primer, 10 ng/µl of gDNA and distilled water to  
385 15 µl. The thermal cycles included initiation for one cycle at 95°C for 3 min followed by 40  
386 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 30 s, extension at 72°C for 45 s,  
387 and a final extension at 72°C for 10 min. The SYBR green signal was read every annealing cycle  
388 and reported as threshold cycle (Ct). Efficiency of programmed CRISPR/Cas editing was  
389 estimated as the ratio of Ct<sub>OUT</sub>:Ct<sub>OVR</sub> from experimental (A) compared with Ct<sub>OUT</sub>:Ct<sub>OVR</sub> of  
390 control group (B) as described<sup>17</sup>. The Ct<sub>OUT</sub>:Ct<sub>OVR</sub> ratio from control group would equal '1'  
391 (CRISPR efficiency = 0) since differences were not seen in Ct value from OUT and OVR  
392 primers. By contrast, the OVR primer is anticipated to be less efficient than the OUT primer for  
393 the experimental group, and hence the Ct<sub>OUT</sub>:Ct<sub>OVR</sub> is less than '1'. Here, we calculated %  
394 mutation indirectly by subtraction of the CRISPR/Cas9 efficiency value from '1', as indicated  
395<sup>17,32</sup>.

$$\begin{aligned} \text{Efficiency (F)} &= \frac{\text{Average Ct OUT}}{\text{Average Ct OVR}} \\ \text{CRISPR/Cas9 efficiency} &= \frac{F_{\Delta Ov-grn-1}}{F_{\text{Control}}} \\ \text{Mutation rate} &= 100\% - \text{CRISPR Cas9 efficiency} \end{aligned}$$

### 406 Illumina-based deep sequencing

407  
408 The MiSeq NGS library was constructed from pooled DNA samples of *Ov-grn-1* gene-edited  
409 adult liver flukes at days 14 and 21 post-transfection. The 173 bp amplicon flanking the DSB  
410 was amplified from MiSeq-F (position 1496-1514 nt): 5' TTCGAGATTCGGTCAGCCG-3' and

411 MiSeq-R (position 1649-1668 nt): 5'GCACCAACTCGCAACTTACA-3' primers (**Fig. 1b**). The  
412 amplicon was purified (Agencourt AMPure XP beads, Beckman) and ligated with Gene Read  
413 Adaptors Set A (Qiagen) and Illumina compatible adaptor(s) and barcode(s) using QIAseq 1-step  
414 Amplicon library kit (Qiagen). The library was quantified using a GeneRead Library Quant Kit  
415 (Qiagen) with Illumina index/barcode specific primers included in the kit. The concentration of  
416 the MiSeq library was read against known standard libraries provided with the Library Quant  
417 Kit. NGS was performed at GENEWIZ, South Plainland, NJ). The MiSeq NGS reads were  
418 trimmed of index/adaptor and primer out sequences prior to further analysis for programmed  
419 mutations by SnapGene software (GSL Biotech LLC) and CRISPResso analysis platform<sup>18,19</sup>  
420 against the target amplicon of the reference (WT) *Ov-grn-1* gene.

## 421 422 **Illumina-based deep sequencing**

423  
424 The MiSeq NGS library was constructed from pooled DNA samples of *Ov-grn-1* gene-edited  
425 adult liver flukes at days 14 and 21 post-transfection. The 173 bp amplicon flanking the DSB  
426 was amplified from *Ov-grn-1* MiSeq-F (position 1496-1514 nt): 5'  
427 TTCGAGATTCGGTCAGCCG-3' and *Ov-grn-1* MiSeq-R (position 1649-1668 nt):  
428 5'GCACCAACTCGCAACTTACA-3' primers (**Fig. 1b**). The amplicon was purified using  
429 Agencourt AMPure XP beads (Beckman) and ligated with index/barcoded adapters compatible  
430 with the Illumina system using Gene Read Adaptors Set A with the QIAseq 1-step Amplicon  
431 library kit (Qiagen). The library was quantified using a GeneRead Library Quant Kit (Qiagen)  
432 with Illumina index/barcode specific primers supplied in the kit. The concentration of the MiSeq  
433 library was compared with known standard libraries provided with the Library Quant Kit. The  
434 MiSeq reads (NGS performed by GENEWIZ, South Plainfield, NJ) were trimmed of  
435 index/adaptor and primer out sequences before downstream analysis for programmed mutations  
436 by SnapGene software (GSL Biotech LLC) and the CRISPResso platform<sup>18,19</sup> against the target  
437 amplicon from the reference WT *Ov-grn-1* gene.

## 438 439 **Cell proliferation and *in vitro* wound healing assay**

440  
441 To evaluate the effect of *Ov-grn-1* gene editing on liver fluke-driven proliferation of human  
442 cholangiocytes, motile WT or  $\Delta$ *Ov-grn-1* adult flukes were co-cultured with cell of the human  
443 cholangiocyte cell line H69 in 24-well Trans-well plates (3 wells per groups)<sup>7</sup> containing a 4  
444  $\mu$ m pore size membrane separating the upper and lower chambers (Corning). In brief, 15,000 H69  
445 cells were seeded into the lower chamber of the plate and cultured with complete medium  
446 containing DMEM/F12 supplemented with 1 $\times$  antibiotic, 10% fetal bovine serum, 25  $\mu$ g/ml  
447 adenine, 5  $\mu$ g/ml insulin, 1  $\mu$ g/ml epinephrine, 8.3  $\mu$ g/ml holo-transferrin, 0.62  $\mu$ g/ml  
448 hydrocortisone, 1.36  $\mu$ g/ml T3 and 10 ng/ml EGF<sup>33</sup> for 24 hours, after which the cells were  
449 fasted for 4-6 hours in medium supplemented with only one twentieth of the growth factor  
450 content of complete medium. Five viable *O. viverrini* adult flukes that had been transfected (or  
451 not) with CRISPR/Cas9 *Ov-grn-1* plasmid in a total of 500  $\mu$ l of RPMI (or medium alone) were  
452 placed into the upper chamber of each well. The number of cells in each well was determined at  
453 days 1, 2 and 3 using 1 $\times$  PrestoBlue cell viability reagent (Invitrogen)<sup>34</sup> and added to cells at  
454 37°C for up to 1 hour. Cell number was determined at 570 nm and calculated from a standard  
455 curve before transforming into relative growth compared to control groups. Cell proliferation  
456 assay was carried out in triplicate.

457  
458 To assess the effect of *Ov-grn-1* knockout on *in vitro* wound healing,  $3 \times 10^5$  H69 cholangiocytes  
459 in monolayer were grown in 6-well Trans-well plates with a 4  $\mu\text{m}$  pore size. H69 cells were  
460 cultured in complete media for 2 days at 37°C then transferred to incomplete media overnight.  
461 Monolayers in each well were scratched using a sterile 200  $\mu\text{l}$  autopipette tip<sup>7,8,35</sup> and washed  
462 with PBS twice to remove disconnected cells or debris. Ten transfected adult or control flukes  
463 were added to the upper chamber of the Trans-well plate containing the wounded cell monolayer  
464 in the lower chamber. The migration rate of cell wound closure was measured at 0, 12, 24 and 36  
465 hours, respectively. Trans-well plates were imaged using an inverted microscope (Nikon) and  
466 images of all groups were captured at all-time points quantitatively using Adobe Photoshop CS6.  
467 The distances between different sides of the scratch were measured by drawing a line in the  
468 middle of the scratch on the captured image<sup>7,8,35,36</sup>. The analysis of wound healing was carried  
469 three times.

### 470 471 **Infection of hamsters with *Ov-grn-1* gene-edited NEJs and assessment of hepatobiliary** 472 **histopathology**

473  
474 Thirty male Syrian golden hamsters, 6-8 weeks of age, were obtained from the Animal Unit,  
475 Faculties of Medicine, Khon Kaen University (approval number ACUC-KKU-61/60). The  
476 hamsters were randomly divided into three groups of 10 per group: uninfected control, infected  
477 with WT flukes and infected with  $\Delta Ov-grn-1$  flukes. Each hamster was infected with 100 active  
478 NEJs through intragastric intubation; the uninfected control group was fed normal saline solution  
479 instead of NEJ<sup>23</sup>. Hamsters (5 animals per cage) were contained under conventional conditions  
480 and fed a stock diet (C.P. Ltd., Thailand) and water *ad libitum* until they were euthanized<sup>23</sup>.  
481 Following euthanasia, five hamsters from each group were necropsied for histopathological  
482 assessment of the hepatobiliary tract at day 14 and at day 60 post-infection<sup>23</sup>. The hamsters were  
483 euthanized by overdose of anesthesia with diethyl ether. Subsequently, blood was obtained by  
484 cardiac puncture and the livers were removed. Fluke numbers were counted from two livers of  
485 both, WT and  $\Delta Ov-grn-1$  groups at day 60 after infection of hamsters and compared with  
486 unpaired two-tailed *t*-test. The left and right lobes of the liver from five hamsters were dissected,  
487 cross-sectioned and each lobe was divided into three parts. The liver fragments were fixed in  
488 10% buffered formalin and stored overnight at 4°C before processing. Formalin-fixed liver was  
489 dehydrated through an ethanol series (70, 95 and 100%), cleared in xylene and embedded in  
490 paraffin. Paraffin embedded sections of 4  $\mu\text{m}$  thickness, cut by microtome, were stained with  
491 hematoxylin and eosin (H&E) or Picro-Sirius Red, or probed with anti-ACTA2 antibodies, and  
492 analyzed for pathologic changes (below).

### 493 494 **Biliary hyperplasia**

495  
496 H&E staining was used to assess pathological changes. The sections were deparaffinized in  
497 100% xylene, rehydrated with descending series of alcohol, stained with H&E for 5 min,  
498 dehydrated with an ascending series of alcohol, cleared with 100% xylene, mounted on a slide  
499 with permount media, and slides were dried at 37°C overnight and photographed under light  
500 microscopy. Images (200 $\times$ ) from H&E stained liver sections from 5 untreated control hamsters  
501 or 5 hamsters per treatment group (WT and  $\Delta Ov-grn-1$  groups) were assessed. Thickness (width)  
502 of the bile duct epithelium from each thin liver section was measured with ImageJ at eight

503 equidistant positions around the bile duct. To compensate for outliers the median width for each  
504 bile duct was used for graphing and analysis. The two-way ANOVA Holm-Sidak multiple  
505 comparison test was used to compare each group at each time point.

506

## 507 **Fibrosis**

508

509 Two stains were used separately to assess biliary fibrosis. First, sections were stained with Picro-  
510 Sirius Red (Abcam, Cambridge Science Park, UK). Sufficient Picro-Sirius Red solution was  
511 applied to completely cover the tissue sections on the slide, the stained slide was incubated at  
512 ambient temperature for 60 min, rinsed in two changes of acetic acid solution, and dehydrated  
513 through two changes of absolute ethanol. Slides were cleared with 100% xylene, mounted in Per-  
514 mount, dried at 37°C overnight, and examined and photographed by light microscopy to  
515 document collagen surrounding the bile ducts. ImageJ was used to auto-color balance the images  
516 using the macro written by Vytas Bindokas; Oct 2006, Univ. of Chicago  
517 ([https://digital.bsd.uchicago.edu/docs/imagej\\_macros/\\_graybalancetoROI.txt](https://digital.bsd.uchicago.edu/docs/imagej_macros/_graybalancetoROI.txt)) followed by  
518 application of the MRI fibrosis tool to determine percentage area of red-stained fibrosis at default  
519 settings (red 1: 0.148, green 1: 0.772, blue 1: 0.618, red 2: 0.462, green 2: 0.602, blue 2: 0.651,  
520 red 3: 0.187, green 3: 0.523, blue 3: 0.831)<sup>37</sup>. Twenty discrete images (200×) stained with Picro-  
521 Sirius Red from each animal (five hamsters per treatment group) were assessed (in total, 100  
522 images per group). Kruskal-Wallis with Dunn's multiple comparison test was used to compare  
523 the findings due to the range of data points among the groups.

524

525 Fibrosis was also assessed via levels of smooth muscle alpha-actin (ACTA2). Liver sections  
526 from hamsters at day 60 post-infection were deparaffinized three times with 100% xylene, 5 min  
527 each. Sections were rehydrated with ascending series of ethanol; 100%, 3 times, 3 min each,  
528 95% 3 times, 3 min each, 70% for 3 min, followed by thorough washing in tap water for 5 min,  
529 distilled water for 5 min, and PBS for 5 min. Thereafter, slides were incubated in citrate buffer  
530 pH 6.0 (citric acid (anhydrous) 1.92 g and Tween 20 0.5 ml in total volume of DW 1000 ml) at  
531 110°C for 5 min, allowed to cool for 20 min, and then washed in PBS 3 times, 5 min each.  
532 Sections were then blocked with 5% bovine serum albumen (BSA) for 30 min in a humidified  
533 chamber and washed in PBS 3 × 3 min each with occasional shaking. The slides were probed  
534 with Alexa Fluor 594 –labeled anti-ACTA2 antibody (Abcam) diluted 1:200 in 1% BSA in  
535 PBST, 18 hours at 4°C in a humidified atmosphere. Lastly, slides were washed in PBS 3 × 3 min  
536 each with occasional shaking, mounted in glycerol diluted 1:4 with PBS and examined under  
537 bright and fluorescence light (Zeiss Axio Observer, with AxioVision SE64 Rel. 4.9.1 software,  
538 Jena, Germany). Images with a bile duct containing a fluke were selected and ImageJ was used  
539 to manually select a narrow strip surrounding the bile duct epithelial layer that excluded potential  
540 blood vessels (any enclosed curved oval-like shape). Three liver regions not including the bile  
541 duct or blood vessels were manually selected for background fluorescence measurements, each  
542 comprising 5-10% of the image. The fluorescence intensity of the bile duct epithelial strip was  
543 measured and blanked against the average of the three background regions and reported as  
544 average intensity per cm<sup>2</sup> at 300 PPI (pixels per inch). A total of 25-30 distinct bile duct images  
545 per group (3 animals) were assessed. Zero values from the uninfected group were deemed to  
546 have a value of 1 to allow a log axis. The groups were compared with one-way ANOVA with  
547 Holm-Sidak multiple comparison test.

548

549 **ACKNOWLEDGMENTS**

550

551 We thank Suwit Balthaisong for technical assistance. This study was supported by the Thailand  
552 Research Fund through the Royal Golden Jubilee PhD Program (grant no. PHD/0111/2557 to PA  
553 and TL), the National Cancer Institute (NCI), US National Institutes of Health (NIH) award  
554 R01CA CA164719 (AL, TL, PJB,) and the National Health and Medical Research Council  
555 (NHMRC award APP1085309 to AL, JS and TL, and senior principal research fellowship  
556 APP1117504 to AL). The content is solely the responsibility of the authors and does not  
557 necessarily represent the official views of the NIAID, NCI, NIH or NHMRC.

558

559 **AUTHOR CONTRIBUTIONS**

560

561 T. Laha, P.J. Brindley, W. Ittiprasert , P. Arunsan, N. D. Young, A. Loukas, J. Sotillo, M. Smout,  
562 S. Chaiyadet, C. Cochran, and V. Mann conceived and designed the research; P. Arunsan, M.  
563 Smout, J. Sotillo, S. Karinshak and W. Ittiprasert performed the research; P. Arunsan and M.  
564 Smout recorded the findings ; T. Laha, P.J. Brindley, M. Smout and W. Ittiprasert contributed  
565 reagents and analytic tools; T. Laha, P.J. Brindley, M. Smout, J. Sotillo and P. Arunsan  
566 completed the experiments; T. Laha, P. Arunsan, W. Ittiprasert, J. Sotillo and M. Smout  
567 analyzed data; T. Laha, P. Arunsan, W. Ittiprasert, M. Smout, A. Loukas and P.J. Brindley  
568 prepared figures and wrote the paper.

569

570 The authors declare no competing interests.

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594 **Figure legends**

595

596 **Figure 1 CRISPR/Cas9-mediated gene editing strategy to knock-out *Ov-grn-1* in adult**  
597 ***Opisthorchis viverrini* liver flukes.** **a**, Schematic depiction of *Ov-grn-1* gene with CRISPR/Cas9  
598 target site in first exon marked with green arrow. **b**, The exon1, 2 and 3 location of *Ov-grn-1*  
599 gene, size of 6,267 bp and gRNA targeting exon1: gRNA sequence is blue color and PAM is red  
600 in bracket. Primer pairs were used to detect mRNA expression levels by using RT-qPCR assay  
601 (*Ov-grn-1* RT- forward or RT-F and *Ov-grn-1* RT-reverse or RT-R), Tri-primers were used to  
602 detect the % relative fold amplicon or mutations (outside-forward or OUT-F, overlap-forward or  
603 OVR-F and reverse primer or OUT/OVR-R) and MiSeq forward and reverse (MiSeq-F and  
604 MiSeq-R) primers were used to prepare the NGS amplicon. **c**, CRISPR/Cas9-induced adult  
605 fluke genomic insertion (red bars) and deletion (black bars) mutations (INDELs) detected in the  
606 *Ov-grn-1* gene; CRISPR target site is denoted by the green arrow. Average mutation length is  
607 plotted against *Ov-grn-1* gene amplicon position in base pairs (bp). **d**, Somatic tissues of  
608 individual adult worms (in triplicate per time per group) were solubilized, electrophoresed in  
609 SDS-PAGE gels, transferred to nitrocellulose membrane and probed with anti-*Ov-GRN-1* rabbit  
610 antibody. WT: wild type control fluke tissues; D1-21:  $\Delta$ *Ov-grn-1* fluke tissues sampled the arrow  
611 highlighting the ~9 kDa *Ov-GRN-1* band at different days post-transfection and  $\Delta$ *Ov-grn-1*  
612 flukes show similar *Ov-TSP-2* protein (control antibody) expression levels. D1-21 = protein  
613 products from flukes day 1-21 post  $\Delta$ *Ov-grn-1* treatment. Western blot panels of probed with  
614 anti-*Ov-TSP-2* rabbit antibody, the arrow highlighting the ~24 kDa *Ov-TSP-2* band. **e**, Reduced  
615 expression of *Ov-grn-1* mRNA and *Ov-GRN-1* protein after transfection of adult flukes with *Ov-*  
616 *grn-1* CRISPR/Cas9 construct using quantitative real-time PCR (mRNA) and densitometry  
617 conversion of Western blot signals (protein). Data are plotted relative to wild type (WT) fluke  
618 values (100%) as an average percentage from 3 replicates with SD error bars. \*\*\*\* =  $P < 0.0001$   
619 compared to WT fluke protein (black) or RNA (pink) at each time point with two-way ANOVA  
620 Holm-Sidak multiple comparison test.

621 **Figure 2  $\Delta$ *Ov-grn-1* adult fluke ES products induce less *in vitro* cell proliferation and**  
622 **wound repair.** **a**, Representative cell proliferation images of H69 immortalized human  
623 cholangiocyte cell line co-cultured with flukes in Trans-well plates; mock transfected (top) and  
624  $\Delta$ *Ov-grn-1* (bottom) groups are shown at day 3. **b**, Reduced cell proliferation induced by  $\Delta$ *Ov-*  
625 *grn-1* fluke ES products, as shown in panel a, quantified from days 1-6. Data is plotted as  
626 average relative percentage to cells cultured with “no flukes”. **c**, Representative image of H69  
627 cholangiocyte scratch wound repair when cells were co-cultured in Trans-well plates with flukes.  
628 Mock transfected (top) and  $\Delta$ *Ov-grn-1* (bottom) groups are shown at 0 and 36 h post-scratch  
629 wounding. Dotted line shows the edge of the wound. **d**, Scratch wound repair assay quantified  
630 from 0 to 36 hours, revealing diminished healing in the  $\Delta$ *Ov-grn-1* group. Panels **b** and **d**: mean  $\pm$   
631 SD, three replicates; \*\*\*\* $P < 0.0001$  compared to wild type flukes with two-way ANOVA Holm-  
632 Sidak multiple comparison test.

633

634 **Figure 3  $\Delta$ *Ov-grn-1* newly excysted juveniles can infect hamsters and drive reduced short-**  
635 **term pathology.** Images of infective metacercariae (**a**) and newly excysted juvenile flukes  
636 (NEJ) (**b**). **c**, *Ov-grn-1* mRNA expression in mock-transfected and  $\Delta$ *Ov-grn-1* flukes over 5 days  
637 as quantified with qPCR and plotted relative to the wild type (WT) untreated group; mean  $\pm$  SD,  
638 three replicates; \*\*\*\* =  $P < 0.0001$  compared to WT flukes with two-way ANOVA Holm-Sidak  
639 multiple comparison test at each time point. **d**, Representative image of 400x magnification of

640 H&E stained thin section from hamster liver at 14 days after infection with WT flukes. **e**,  
641 Representative image of H&E stained thin sections showing hamster liver 14 days after infection  
642 with  $\Delta Ov-grn-1$  flukes. **f**, Representative image of H&E stained thin section of control,  
643 uninfected hamster liver, which shows healthy, organized pavement-like profile of the cells of  
644 the biliary epithelium (BE) enclosing the lumen of the bile duct (BD) near a blood vessel (BV)  
645 within the liver (L). Infection by WT flukes (panel **d**) revealed thickened, disordered epithelium  
646 adjacent to the parasite (*Ov*). Infection with  $\Delta Ov-grn-1$  flukes (panel **e**) revealed a bile duct  
647 epithelium more closely resembling the normal, uninfected hamster. **g**, Epithelium  
648 width/hyperplasia (green bracket) was quantified using ImageJ and plotted as the mean  $\pm$  SD of  
649 five biological replicates (hamsters). Significant difference were apparent when compared to the  
650 uninfected group using the two-way ANOVA with Holm-Sidak multiple comparison test:  
651  $**P<0.01$  and  $****P<0.0001$ , and wild-type compared to  $\Delta Ov-grn-1$ ,  $\# P<0.05$  and  
652  $####P<0.0001$ .

653  
654 **Figure 4. Diminished level of fibrosis in hamsters during chronic infection with gene-edited**  
655  **$\Delta Ov-grn-1$  liver flukes.** Panel **a**, Adult fluke numbers were counted from the livers at day 60  
656 post-infection and shown as the average and range for two hamsters per group. Fluke counts  
657 showed minimal (12%; *ns*) difference between the wild type (WT) and  $\Delta Ov-grn-1$  groups. **b**,  
658 Representative images of Sirius red stained hamster liver (L) sections from uninfected animals  
659 show minimal collagen fibrosis (fb) deposition, stained red surrounding the blood vessel (BV)  
660 and bile ducts (BD) with normal biliary epithelia (BE). Livers from hamsters infected with WT  
661 flukes (*Ov*) show heavy collagen deposition with elongated BE cells adjacent to resident flukes. .  
662  $\Delta Ov-grn-1$  fluke infected livers showed substantial collagen deposition compared to uninfected  
663 liver sections, yet showed far less than the livers infected with WT flukes. **c**, Liver fibrosis  
664 quantified with ImageJ MRI-fibrosis plugin shown as a violin plot. 100 images containing bile  
665 ducts from 20 sections (5 animals) per group showing SD as a vertical line with the median  
666 indicated by the central black dot.  $\Delta Ov-grn-1$  group showed a 23% reduction in median fibrosis  
667 compared to WT group. The width of the “violin-shape” represents measurement frequency.  
668 Kruskal-Wallis with Dunn’s multiple comparison test used to compare groups. Against  
669 uninfected:  $****P<0.0001$ , and  $\Delta Ov-grn-1$  against WT:  $### P<0.001$ . **d**, Representative  
670 immunofluorescence/bright field overlay images of liver sections probed with anti-ACTA2  
671 antibody with fluorescence intensity shown on a blue/green/red scale. ACTA2 protein is always  
672 detected in my fibroblasts surrounding blood vessels, but not near normal bile ducts. When  
673 detected near the BE layer it is suggestive of myofibroblast generation as a response to BE  
674 damage. The upper panels (Overlay) show a wide view of the liver sections with a boxed region  
675 that highlights a section of interest that is magnified in the lower panels (Zoom). Hamster liver  
676 sections exhibited intense fluorescence (arteries: red/green, veins: blue/green) surrounding BVs  
677 whereas only minimal fluorescence was seen near BD in livers of uninfected hamsters The  
678 highlighted magnified (Zoom) panels show WT infected animal livers with weak (blue) but  
679 consistent ACTA2 staining surrounding thickened BE layer (inner and outer cell edge marked  
680 with orange dotted line) around BDs with WT flukes. Livers from hamsters infected with  $\Delta Ov-$   
681  $grn-1$  flukes show weak and irregular ACTA2 staining surrounding BD. **e**, Quantified levels of  
682 ACTA2 surrounding BDs from hamster liver sections. Violin plot with reverse log<sub>2</sub> Y-axis  
683 showing the ACTA2 intensity (per cm<sup>2</sup> at 300 PPI) surrounding BE from 25-30 discrete BD  
684 images per group (three hamsters) assessed with ImageJ. Zero values from uninfected group  
685 were deemed to have a value of 1 so that a log axis could be plotted. SD indicated as a line with

686 mean value marked as a central black dot and the violin-shape width representing measurement  
687 frequency. ACTA2 staining shows 94% median reduction in  $\Delta Ov-grn-1$  fluke-infected livers  
688 compared to WT fluke-infected animals. One-way ANOVA with Holm-Sidak multiple  
689 comparison test, \*\*\*\* $P < 0.0001$  compared to uninfected and ## $P < 0.001$  compared to  $\Delta Ov-grn-1$   
690 flukes against WT flukes. **f**,  $Ov-grn-1$  mRNA expression levels are reduced in  $\Delta Ov-grn-1$  flukes  
691 compared to WT flukes. Reverse log<sub>10</sub> Y-axis shows the qPCR  $2^{(-\Delta\Delta Ct)}$  results from flukes 60  
692 days after programmed CRISPR/Cas9 gene editing and hamster infection plotted relative to  
693 mean value of the WT infection. The WT group showed a broad level of expression; the mean  
694 expression level for the  $\Delta Ov-grn-1$  flukes was 19.4% of the WT group; Mann-Whitney  
695 nonparametric test, \*\* $P < 0.01$ . While significantly reduced overall, the  $\Delta Ov-grn-1$  fluke group  
696 ranged from no apparent effect to markedly diminished expression of  $Ov-grn-1$ . Mutation  
697 frequency was assessed by assigning the  $\Delta Ov-grn-1$  group of flukes into three sub-groups based  
698 on CRISPR/Cas9 mutation frequency. Eight flukes with highly effective CRISPR gene knock-  
699 out ( $\Delta Ov-grn-1$ :  $Ov-grn-1 < 10\%$  expression), seven flukes with modest levels of transcript  
700 knock-out ( $\Delta Ov-grn-1$ : 10-70%  $Ov-grn-1$ ) and 10 flukes with little or no effect ( $\Delta Ov-grn-1$ :  $Ov-$   
701  $grn-1$  100-120%). The mean mutation frequency amongst the three  $\Delta Ov-grn-1$  sub-groups was  
702 2.7%.

703

704

## 705 References

706

- 707 1. Sripa, B. *et al.* Opisthorchiasis and Opisthorchis-associated cholangiocarcinoma in  
708 Thailand and Laos. *Acta Trop* **120 Suppl 1**, S158-68 (2011).
- 709 2. Pagano, J.S. *et al.* Infectious agents and cancer: criteria for a causal relation. *Semin*  
710 *Cancer Biol* **14**, 453-71 (2004).
- 711 3. Laha, T. *et al.* Gene discovery for the carcinogenic human liver fluke, *Opisthorchis*  
712 *viverrini*. *BMC genomics* **8**, 189 (2007).
- 713 4. Khuntikeo, N. *et al.* Cohort profile: cholangiocarcinoma screening and care program  
714 (CASCAP). *BMC Cancer* **15**, 459 (2015).
- 715 5. Khuntikeo, N., Loilome, W., Thinkhamrop, B., Chamadol, N. & Yongvanit, P. A  
716 Comprehensive Public Health Conceptual Framework and Strategy to Effectively  
717 Combat Cholangiocarcinoma in Thailand. *PLoS Negl Trop Dis* **10**, e0004293 (2016).
- 718 6. Brindley, P.J. & Loukas, A. Helminth infection-induced malignancy. *PLoS Pathog* **13**,  
719 e1006393 (2017).
- 720 7. Papatpremsiri, A. *et al.* Suppression of *Ov-grn-1* encoding granulin of *Opisthorchis*  
721 *viverrini* inhibits proliferation of biliary epithelial cells. *Exp Parasitol* **148**, 17-23 (2015).
- 722 8. Smout, M.J. *et al.* Carcinogenic Parasite Secretes Growth Factor That Accelerates  
723 Wound Healing and Potentially Promotes Neoplasia. *PLoS Pathog* **11**(2015).
- 724 9. Hoffmann, K.F., Brindley, P.J. & Berriman, M. Medicine. Halting harmful helminths.  
725 *Science* **346**, 168-9 (2014).
- 726 10. Hsu, P.D., Lander, E.S. & Zhang, F. Development and applications of CRISPR-Cas9 for  
727 genome engineering. *Cell* **157**, 1262-78 (2014).
- 728 11. Sander, J.D. & Joung, J.K. CRISPR-Cas systems for editing, regulating and targeting  
729 genomes. *Nat Biotechnol* **32**, 347-55 (2014).
- 730 12. Waaijers, S. & Boxem, M. Engineering the *Caenorhabditis elegans* genome with  
731 CRISPR/Cas9. *Methods* **68**, 381-8 (2014).



- 732 13. Lok, J.B., Shao, H., Massey, H.C. & Li, X. Transgenesis in Strongyloides and related  
733 parasitic nematodes: historical perspectives, current functional genomic applications and  
734 progress towards gene disruption and editing. *Parasitology* **144**, 327-342 (2017).
- 735 14. Gang, S.S. *et al.* Targeted mutagenesis in a human-parasitic nematode. *PLoS Pathog* **13**,  
736 e1006675 (2017).
- 737 15. Young, N.D. *et al.* The *Opisthorchis viverrini* genome provides insights into life in the  
738 bile duct. *Nat Commun* **5**, 4378 (2014).
- 739 16. Shah, A.N., Davey, C.F., Whitebirch, A.C., Miller, A.C. & Moens, C.B. Rapid reverse  
740 genetic screening using CRISPR in zebrafish. *Nat Methods* **12**, 535-40 (2015).
- 741 17. Yu, C., Zhang, Y., Yao, S. & Wei, Y. A PCR based protocol for detecting indel  
742 mutations induced by TALENs and CRISPR/Cas9 in zebrafish. *PLoS One* **9**, e98282  
743 (2014).
- 744 18. Canver, M.C. *et al.* Integrated design, execution, and analysis of arrayed and pooled  
745 CRISPR genome-editing experiments. *Nat Protoc* **13**, 946-986 (2018).
- 746 19. Pinello, L. *et al.* Analyzing CRISPR genome-editing experiments with CRISPResso. *Nat*  
747 *Biotechnol* **34**, 695-7 (2016).
- 748 20. Guido, M., Rugge, M., Leandro, G., Fiel, I.M. & Thung, S.N. Hepatic stellate cell  
749 immunodetection and cirrhotic evolution of viral hepatitis in liver allografts. *Hepatology*  
750 **26**, 310-4 (1997).
- 751 21. Sithithaworn, P., Pipitgool, V., Srisawangwong, T., Elkins, D.B. & Haswell-Elkins, M.R.  
752 Seasonal variation of *Opisthorchis viverrini* infection in cyprinoid fish in north-east  
753 Thailand: implications for parasite control and food safety. *Bull World Health Organ* **75**,  
754 125-31 (1997).
- 755 22. Papatpremsiri, A. Effect of radiation attenuation of metacercariae and gene silencing  
756 targeting granulins on infection with *Opisthorchis viverrini*, Doctor of Philosophy in  
757 biomedical science, Khon Kaen University, Thailand (2014).
- 758 23. Sripa, B. & Kaewkes, S. Gall bladder and extrahepatic bile duct changes in *Opisthorchis*  
759 *viverrini*-infected hamsters. *Acta Tropica* **83**, 29-36 (2002).
- 760 24. Piratae, S. *et al.* Molecular characterization of a tetraspanin from the human liver fluke,  
761 *Opisthorchis viverrini*. *PLoS Negl Trop Dis* **6**, e1939 (2012).
- 762 25. Yang, H., Wu, J.J., Tang, T., Liu, K.D. & Dai, C. CRISPR/Cas9-mediated genome  
763 editing efficiently creates specific mutations at multiple loci using one sgRNA in  
764 *Brassica napus*. *Sci Rep* **7**, 7489 (2017).
- 765 26. Chan, S.N., Abu Bakar, N., Mahmood, M., Ho, C.L. & Shaharuddin, N.A. Molecular  
766 cloning and characterization of novel phytocystatin gene from turmeric, *Curcuma longa*.  
767 *Biomed Res Int* **2014**, 973790 (2014).
- 768 27. Chen, H., Rangasamy, M., Tan, S.Y., Wang, H. & Siegfried, B.D. Evaluation of five  
769 methods for total DNA extraction from western corn rootworm beetles. *PLoS One* **5**,  
770 e11963 (2010).
- 771 28. Vasquez, J.J., Wedel, C., Cosentino, R.O. & Siegel, T.N. Exploiting CRISPR-Cas9  
772 technology to investigate individual histone modifications. *Nucleic Acids Res* (2018).
- 773 29. Schmittgen, T.D. & Livak, K.J. Analyzing real-time PCR data by the comparative C(T)  
774 method. *Nat Protoc* **3**, 1101-8 (2008).
- 775 30. Strannegard, O. & Yurchison, A. Formation of rabbit reaginic antibodies to protein and  
776 haptens-protein conjugates. *Immunology* **16**, 387-97 (1969).

- 777 31. Chaiyadet, S. *et al.* Suppression of mRNAs encoding CD63 family tetraspanins from the  
778 carcinogenic liver fluke *Opisthorchis viverrini* results in distinct tegument phenotypes.  
779 *Sci Rep* **7**, 14342 (2017).
- 780 32. Sentmanat, M.F., Peters, S.T., Florian, C.P., Connelly, J.P. & Pruett-Miller, S.M. A  
781 Survey of Validation Strategies for CRISPR-Cas9 Editing. *Sci Rep* **8**, 888 (2018).
- 782 33. Ninlawan, K. *et al.* *Opisthorchis viverrini* excretory/secretory products induce toll-like  
783 receptor 4 upregulation and production of interleukin 6 and 8 in cholangiocyte. *Parasitol*  
784 *Int* **59**, 616-21 (2010).
- 785 34. Tynan, R.J. *et al.* A comparative examination of the anti-inflammatory effects of SSRI  
786 and SNRI antidepressants on LPS stimulated microglia. *Brain Behav Immun* **26**, 469-79  
787 (2012).
- 788 35. Liang, C.C., Park, A.Y. & Guan, J.L. In vitro scratch assay: a convenient and inexpensive  
789 method for analysis of cell migration in vitro. *Nat Protoc* **2**, 329-33 (2007).
- 790 36. Smout, M.J. *et al.* Infection with the carcinogenic human liver fluke, *Opisthorchis*  
791 *viverrini*. *Mol Biosyst* **7**, 1367-75 (2011).
- 792 37. M. A. Pereira. Tratamento com células derivadas do fígado embrionário retarda a  
793 progressão da fibrose hepática em ratos, Tese de Doutorado, Universidade de São Paulo,  
794 Brazil (2016).
- 795

Figure 1




Figure 2





Figure 3



**Figure 4**

